Skip to content
About Us
Science
Pipeline
News & Resources
About Us
Science
Pipeline
News & Resources
Contact Us
News
May 4, 2021
Vivace Therapeutics announces dosing of first cohort of patients with its first-in-class TEAD inhibitor
Research and Publications
VIEW ALL
Publications and Presentations
March 7, 2013
The Hippo Pathway and Human Cancer
READ MORE
Publications and Presentations
November 5, 2015
Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer
READ MORE
News
June 28, 2017
Vivace Therapeutics Comes out of Stealth with $40 Million to Turn Novel Biology into First-in-Class Cancer Therapeutics
READ MORE
